LTRN Lantern Pharma Inc

$LTRN let‘s reverse split 😂🤣😂🤣! IMO Sharma has no LP-300 Partnering, no OMAI-financing, nothing!!

$LTRN Lantern Pharma Inc - Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

$LTRN Back in August I said it's too risky. I said they will do diluting capital injections, and the next one won't bring them to cash flow positive, so will need more. Many more. Looks like I was right. It's kind of sad, but biotech is a harsh environment now. It will be difficult for newcomers to raise enough capital to bring their drugs to market. I really hope for good trial results for $LTRN so their SP will do a big jump to the upside.

$LTRN an offering at $1.09, then a delisting notice. This guy sharma talked this shit up with the ai tool and spin off. So far, he’s done the opposite of what he said he would which was to create shareholder value. He has lost some credibility.

$LTRN The one thing I hold on to is the tight capital structure. They will only have 17-18MM shares outstanding fully dilutive which no biotech can remotely be anywhere in the ballpark with all the trials and 2 subsidiaries. No where.

$LTRN One concern I have as a LTRN shareholder is management’s track record on timelines. Several clinical milestones have been delayed, the dedicated withZeta investor webinar announced for June apparently never happened, and now OMAI was announced for “mid-September.” Delays happen in biotech. But a webinar isn’t a clinical trial. Consistently meeting communicated timelines matters for management credibility. Otherwise, investors inevitably start questioning other forward-looking statements as well, including LP-300 partnering discussions, OMAI financing and commercial interest. I hope Lantern delivers this one as communicated.

$LTRN Whether there are gains or losses, it is sad to see LANTERN at this valuation because I still think it’s a “sleeping giant”. I really hope the green road taken this week is the road to back to a decent value, waiting for great news.

$LTRN I can't get into the head of the CEO but the board knew of all of this. They did the miminal direct offering, IMO, or they could have unloaded. Maybe I'm crazy.

$LTRN all fast track drug approvals on all they LTRN have, last year guy at FDA said on CNBC any new drugs the companies get 100 million each drug Trump made the deal what the guy said. I been waiting.. I want MONEY!!!

$LTRN So far I'm wrong. I'll be the first to admit it. They had the ATM so I'm still wondering.

$LTRN Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

$LTRN How important will LTRN Artificial Intelligence be, once other Companies transition into Quantum assisted AI? Just wondering... I have no $LTRN Positions, but bullish to a point.

$LTRN I truly believe buying anytime, especially now, is best...when the right news/data/updates come, you wont be able to scoop under 2 or maybe 3 or higher ever again. There are lots of plays out there, but not many that offer a +10x for just being patient. Bullish as eff.

$LTRN Sharma - what about the AI tool revenue, if any?? And the spinoff??? Stock price is not looking good. You need to get results. So far you're not doing a good job. It's been a long time.

$LTRN The SEC will come knocking. Those recent statements went far beyond mere forward-looking statements.

$LTRN sold this stinker after that cnbc pump a couple years ago. Panna’s had a checkered past. Reverse split coming next year.

$LTRN yeah it seems like he was just blowing smoke, hoping the stock would pump based on his rhetoric.

$LTRN Market Potential in Numbers: $4 Billion Annually Global blood cancer market: According to Lantern Pharma’s own analysis and market research, the global market for aggressive B-cell non-Hodgkin lymphomas targeted by LP-284, including mantle cell lymphoma (MCL), is estimated at approximately $4 billion annually (about KRW 5.3 trillion). Three FDA Orphan Drug Designations (ODDs): LP-284 has already received FDA Orphan Drug Designation for three indications: mantle cell lymphoma (MCL), high-grade B-cell lymphoma (HGBL), and soft tissue sarcoma (STS). The latest patent adds another layer of legal protection around this potentially large rare-cancer market.

$LTRN I am glad that I stayed on the sidelines. I bet we'll see a new ATL after the next diluting capital injection. And there will be many more such diluting capital injections before $LTRN turns cash flow positive.

$LTRN Taking a fing beat down 60 percent red, won't sell it will have to delist. Comon man